Invited commentary  by Gagne, Paul J.
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May 20111328 GagneDr Goodney. If this was a randomized trial, my worry would
be yes. But, of course, we don’t have the control arm in this. And
we wondered how we might study that. This is a real world study,
so it’s a study in which you need not only highly selected patients
and centers of excellence, you would need real world data. So, to
get appropriately large-scale, one would essentially be limited to
administrative or claims data.
After 2005, Medicare Part D would have that informa-
tion available and you could conceivably study those on beta
blockers and those not on beta blockers. The other alternative
would be to implement another regional quality improvement
group that didn’t study beta blockers to see what happened over
time.
Dr Murray. We’ll look forward to it.
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ize” care pre-empted the wisdom of facts gained through multiple
subsequent, well-designed studies and analyses. Medicine may
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1Dr Jens Eldrup-Jorgensen (Portland, Ore). Our study did
ave a number of limitations which may explain the lack of impact
f perioperative beta blocks on postoperative myocardial infarc-
ion. The dose was somewhat low, which may have decreased the
ffectiveness of the medication. We had a relatively low number of
igh-risk patients undergoing high-risk operations, and those are
he ones who would be expected to benefit most from being
tarted on beta blockers prior to operation.
To address Dr. Moneta’s question regarding the issue of
troke in patients on perioperative beta blockers, in the POISE
tudy, they used a very high dose of beta blocker which probably
ontributed to hypotension and postoperative stroke. Although
ypotension has been seen in previous studies, POISE is the only
tudy which identified this high incidence of stroke.INVITED COMMENTARYPaul J. Gagne, MD, Norwalk, Conn
In the past decade, business interests and government policy
makers undertook to “refine” the delivery of health care by pro-
posing guidelines that would codify aspects of patient care delivery.
The proposed impetus was to improve quality and decrease costs
for treating conditions like congestive heart failure, surgical infec-
tions, and vascular surgery-related myocardial infarction. The as-
sumption implicit to these guidelines was that physicians and the
health care systems they participate in were not interested in or able
to improve health care with data-driven strategies. The club of
reimbursement was used to drive these quality initiatives, implying
that physician concern for the welfare of their patients was not
adequate to achieve good results.
The excellent article by Goodney et al1 highlights two very
important points to remember and publicize as we go forward in
the debate on health care reform.
The first is that intelligent, well-trained physicians are better
able to care for their patients than are committees who believe they
have a “special ability” to understand “evidence-based medicine.”
Physicians learn early in their training to read the literature with a
critical eye and to determine how best to apply new science to their
patients. Mandated guidelines are only as good as the data they are
based on. They are not able to accommodate specific patient needs,
nor are they nimble enough to adapt to new data the way individ-
ual physicians do daily. The guidelines urging beta-blockers for
vascular patients are a great example of how rushing to “standard-eem to change glacially at times, but I believe this reflects a careful
nd ongoing critical analysis by physicians of “new science” rather
han ignorance or indifference to patient welfare. We practice
vidence-based medicine daily. Unfortunately, the evidence is
ften not as straightforward as the media and pundits would
urport.
The second important point in this report is that physicians,
onvinced that a new therapy or approach is in their patients’ best
nterest, will adopt it. The physicians in this research consortium
uickly and effectively instituted beta-blocker use, expecting to
mprove their patients’ care. This occurred without financial incen-
ives.
I commend the authors for their scientific contribution on the
ole of beta-blockers in vascular surgery. I also thank them for
ffirming what I believe about our profession. As a group, physi-
ians, with our speciality societies, will do what is best for our
atients. We do not need “Big Brother” herding us to achieve this.
e are our patients’ best advocates and wemust resist the efforts of
oliticians, lawyers, business interests, and insurance vendors to
onvince society otherwise.
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